Neukio Biotherapeutics
About:
Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.
Website: https://www.neukio.com/
Top Investors: Lilly Asia Ventures, IDG Capital, Sherpa Healthcare Partners, CD Capital, Yahui Precision Medicine Fund
Description:
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.
Total Funding Amount:
$90M
Headquarters Location:
Shanghai, Shanghai, China
Founded Date:
2021-01-01
Founders:
Richard Wang
Number of Employees:
51-100
Last Funding Date:
2022-09-02
IPO Status:
Private
Industries:
© 2025 bioDAO.ai